| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
NCT04610658: Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC |
|
|
| Terminated | 1 | 9 | US | Nivolumab, Opdivo, Ipilimumab, Yervoy, Lurbinectedin | H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, Jazz Pharmaceuticals | Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | 03/23 | 03/23 | | |